Nabriva Therapeutics to Present at the Cowen and Company 37th Annual Healthcare Conference
February 27 2017 - 7:00AM
Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage
biopharmaceutical company engaged in the research and development
of novel anti-infective agents to treat serious infections, with a
focus on the pleuromutilin class of antibiotics, today announced
that Colin Broom, M.D., chief executive officer of Nabriva
Therapeutics, will provide a company overview and business update
at the Cowen and Company 37th Annual Healthcare Conference on
Monday, March 6, 2017 at 4:00 p.m. ET. The conference is being held
at the Boston Marriott Copley Place hotel in Boston, Massachusetts.
The presentation will be webcast live and may be accessed by
visiting the "Investors" section of the Company’s web site under
the "Events and Presentations" tab at http://investors.nabriva.com.
A replay of the webcast will be available for 90 days.
About Nabriva Therapeutics AG
Nabriva Therapeutics is a clinical stage biopharmaceutical
company engaged in the research and development of novel
anti-infectives to treat serious bacterial infections, with a focus
on the pleuromutilin class of antibiotics. Nabriva Therapeutics’
medicinal chemistry expertise has enabled targeted discovery of
novel pleuromutilins, including both intravenous and oral
formulations of its lead product candidate. Nabriva Therapeutics’
lead product candidate, lefamulin, is a novel semi-synthetic
pleuromutilin antibiotic with the potential to be the
first-in-class available for systemic administration in
humans. The Company believes that lefamulin is the first
antibiotic with a novel mechanism of action to have reached
late-stage clinical development in more than a
decade. Lefamulin is currently being evaluated in two global,
registrational Phase 3 clinical trials in patients with moderate to
severe CABP. Nabriva Therapeutics believes lefamulin is well
positioned for use as a first-line empiric monotherapy for the
treatment of moderate to severe CABP due to its novel mechanism of
action, targeted spectrum of activity, resistance profile,
achievement of substantial drug concentration in lung tissue and
fluid, oral and IV formulations and a favorable tolerability
profile. Nabriva Therapeutics intends to further pursue development
of lefamulin for additional indications, including the treatment of
acute bacterial skin and skin structure infections (ABSSSI), and is
developing a formulation of lefamulin appropriate for pediatric
use.
Nabriva Therapeutics owns exclusive, worldwide rights to
lefamulin, which is protected by composition of matter patents
issued in the United
States, Europe and Japan.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Nabriva, including but not limited to
statements about the development of Nabriva’s product candidates,
such as plans for the design, conduct and timelines of Phase 3
clinical trials of lefamulin for CABP, the clinical utility of
lefamulin for CABP and Nabriva’s plans for filing of regulatory
approvals and efforts to bring lefamulin to market, the development
of lefamulin for additional indications, the development of
additional formulations of lefamulin, plans to pursue research and
development of other product candidates, and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “likely,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: the uncertainties inherent in the
initiation and conduct of clinical trials, availability and timing
of data from clinical trials, whether results of early clinical
trials or trials in different disease indications will be
indicative of the results of ongoing or future trials,
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals, the availability or
commercial potential of product candidates including lefamulin for
use as a first-line empiric monotherapy for the treatment of
moderate to severe CABP, the sufficiency of cash resources and need
for additional financing and such other important factors as are
set forth under the caption "Risk Factors" in Nabriva’s annual
report on Form 20-F and its prospectus supplement dated November
29, 2016 filed with the United States Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent Nabriva’s views as of the date of this
release. Nabriva anticipates that subsequent events and
developments will cause its views to change. However, while Nabriva
may elect to update these forward-looking statements at some point
in the future, it specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as
representing Nabriva’s views as of any date subsequent to the date
of this release.
CONTACT:
INVESTOR RELATIONS
Will Sargent
Nabriva Therapeutics AG
William.Sargent@nabriva.com
610-813-6406
MEDIA
Katie Engleman
Pure Communications, Inc.
Katie@purecommunicationsinc.com
910-509-3977
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Apr 2023 to Apr 2024